Skip to main content
  • U.S. Department of Health & Human Services
  • National Institutes of Health
NIBIB Logo

En Español | Site Map | Staff Directory | Contact Us

Megamenu

  • Home
  • Research Funding
      • Program Divisions
      • Bioimaging
      • Bioengineering
      • Informatics
      • Training
      • Funding
      • Opportunities
      • Grant Programs
      • Grants Process
      • NIH Initiatives
      • Policies
      • Funding Notices
      • Related Links
      • Research Resources
      • NIH Guide
      • NIH Parent Announcements
      • NIH Submission Dates
      • NIH RePORTER
      • ARRA (2009)
  • COVID-19 @ NIBIB
      • RADx® Tech Program
      • RADx Tech/ATP Program Overview
      • RADx Tech Dashboard
      • RADx Tech/ATP Phase 2 Awards
      • RADx ITAP
      • RADx MARS
      • FAQs
      • RADx Tech FAQs
      • FAQs For NIBIB’s COVID-19 NOSIs
      • Funding
      • Funded Projects
      • Program Contacts
      • RADx Tech Programmatic or Technical Inquiries
      • All Other RADx Tech Applicants
      • SBIR/STTR Applicants
      • All Other Inquiries
  • Labs @ NIBIB
      • Labs
      • Cellular Imaging
      • Dynamics of Macromolecular Assembly
      • Molecular Tracer Imaging
      • Biophotonics
      • Quantitative Imaging
      • Immunoengineering
      • Mechanobiology
      • Shared Resources
      • Instrumentation Development and Engineering Application Solutions (IDEAS)
      • BETA Center
      • Advanced Imaging/Microscopy
      • Biomed Engineering/Physical Science
      • Related Links
      • Scientific Director
      • Affiliated Researchers
      • Summer Internship at NIBIB
      • NIH Intramural Research Program
      • NIH Training
      • Research Resources
      • Board of Scientific Counselors
  • Training & Careers
      • Career Stage
      • Grades P-12
      • Undergraduate
      • Graduate/Clinical Training
      • Postdoctoral Training/Clinical Residency
      • Early Career Investigator
      • Established Investigator
      • Grant Types
      • Individual Fellowship
      • Career Development Awards
      • Institutional Grants
      • Diversity Awards / Programs
      • Resources
      • Active Funding Opportunities
      • Grant Writing
      • Other NIH Resources
      • NIH Intramural Research Program Training Opportunities
      • NIH Intramural Research Program Career Opportunities
      • Podcasts and Webinars
  • Science Education
      • Science Topics
      • Artificial Intelligence (AI)
      • Optical Imaging
      • Drug Delivery Systems
      • Image-Guided Robotic Interventions
      • Ultrasound
      • Magnetic Resonance Imaging (MRI)
      • Computed Tomography (CT)
      • X-Rays
      • Nuclear Medicine
      • View More
      • Games, Apps & Media
      • Medical Imaging App
      • Surgery of the Future
      • WISE
      • The Bionic Man
      • Want to be a Bioengineer?
      • Video Gallery
      • 60 Seconds of Science
      • Fun Facts
      • Resources
      • For Parents/Teachers
      • For Students
      • For General Public
      • Government Resources
      • Glossary
      • DEBUT
      • NIH Office of Science Education
  • News & Events
      • Newsroom
      • Press Releases
      • Science Highlights
      • Grantee News
      • NIBIB in the News
      • Events
      • Upcoming Events
      • Past Events
      • Multimedia
      • Video Gallery
      • Audio Library
      • Photo Galleries
      • Media Resources
      • WISE
      • NIBIB Fact Sheets
      • Strategic Plan
      • EurekAlert
      • Newswise
      • NIH News
      • RePORTER
      • PubMed Central
      • Contact Us
      • nibibpress@mail.nih.gov
      • 301-496-3500
  • About NIBIB
      • Who We Are
      • Mission & History
      • Leadership
      • Director's Corner
      • Organization Chart
      • Advisory Council
      • What We Do
      • Training & Research
      • Diversity, Equity, Inclusion, and Accessibility Programs and Activities
      • Program Fact Sheets
      • Strategic Plan
      • Budget
      • Gift Policy
      • Contact Us
      • Visitor Information
      • Jobs @ NIBIB
      • Staff Directory
      • info@nibib.nih.gov
      • 301-496-3500
      • Locations
      • 9000 Rockville Pike
      • Building 31 Room 1C14
      • Bethesda, MD 20892
      • 6707 Democracy Blvd
      • Suite 202
      • Bethesda, MD 20892
  1. News & Events
  2. Audio Library

Share:

News & Events

  • Newsroom
    • Press Releases
    • Science Highlights
    • Grantee News
    • NIBIB in the News
  • Meetings & Events
    • Upcoming Events
    • Past Events
  • Multimedia
    • Video Gallery
    • Audio Library
    • Photo Galleries
  • Media Resources
    • WISE
    • NIBIB Fact Sheets
    • Strategic Plan
    • EurekAlert
    • Newswise
    • NIH News
    • RePORTER
    • PubMed Central
    • MedlinePlus
  • Glossary
  • Media Contacts
    • nibibpress@mail.nih.gov
    • 301-496-3500

Nanoparticles Evade the Immune System

About This Podcast

By attaching a molecular "passport" to nanoparticles, scientists have found a way to sneak tumor-fighting drugs past cells of the immune system, which would normally engulf the particles, preventing them from reaching their target. 

Health Terms

Cancer, Drug Delivery, Nanotechnology

Program Areas

Transcript

Researchers help nanoparticles carrying tumor-fighting drugs evade the immune system 

Music

Introduction

This is a production of the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health.

Host-Margot Kern

Welcome to the NIBIB science highlights podcast.  Nanoparticles are being used by researchers and most recently in clinical trials to ferry cancer-fighting drugs to tumors.  The use of nanoparticles as a drug delivery mechanism could allow doctors to give patients higher doses of toxic medications while sparing healthy tissue. But the immune system poses a major obstacle to nanoparticle delivery.  That’s because nanoparticles are viewed by immune cells as foreign bodies that should be eliminated.

I recently spoke with an NIBIB grantee, Dr. Dennis Discher, a molecular and cell biophysicist in Chemical and Biomolecular Engineering at the University of Pennsylvania. Discher published a paper in Science on Feberury 22, 2013 in which he describes a new method developed by his lab that helps nanoparticles escape attacks from cells of the immune system, specifically macrophages.

Music ends

Host-Margot Kern

Dr. Discher, for those of us who aren’t familiar with the biology of the immune system, what is a macrophage?

Interviewee-Dennis Discher

A macrophage is a giant (macro), phage or (phagos); it means eating in Greek.  So it’s a giant eater.  And, they’ll eat nanoparticles, they’ll eat microparticles, microbes, but even in implants, if you implant a giant object that’s much bigger than the size of the cell, these cells will try to eat it and in frustration they’ll start fusing and forming a giant multi-nucleated cell, a true giant macrophage.  So often with particles in modern times or implants, we really don’t want this innate immune system to attack what it’s had eons to evolve its expertise to do.

Host-Margot Kern

In the Science paper you attached a protein called CD47 to particles and this prevented them from being recognized by macrophages as foreign.  How was your attention first called to this particular protein?

Interviewee-Dennis Discher

So we, like many other people, in fact I would say most people, as we injected particles into the bloodstream in studies more than ten years ago, we’d find that too many of our particles were taken up by macrophages.  And then a paper appeared in Science about thirteen years ago from a group in St. Louis that reported a mouse that has a specific protein on the surface of really all the cells.  It’s a protein called CD47. They described it as a marker of self as passivating macrophages, as a protein that normally, on normal cells, limits macrophages from eating the cells, and when they knocked it out in a mouse, well they see macrophages in other mice eating cells taken from the mice that had the CD47 protein missing.

Host-Margot Kern

So then, what did your lab do with this new information regarding CD47?

Interviewee-Dennis Discher

There were clearly questions that arose. This was obviously a study in a knockout mouse that left us scratching our heads. And we really wanted to know, would this work on humans and would it work on our particles and maybe other types of materials. I mean macrophage interactions not only with particles but with everything we implant in the body.  

Host-Margot Kern

So then how did your lab determine if human CD47 has the same function as mouse CD47?

Interviewee-Dennis Discher

We aimed to understand human CD47 on human cells starting with human blood cells because mouse blood cells is where this other paper from the St. Louis group had started.  And we worked up to understanding the integration and the differences with mouse and then expressing the protein and showing that  we could put human protein on a plastic microparticle and inhibit phagocytosis in a dish.

Host-Margot Kern

How then did your lab bring this to studies in animals?   

Interviewee-Dennis Discher

About the same time that our paper appeared, a group in Toronto published that there was one strain of mouse and this NOD/SCID strain of mouse, human CD47 interacts with macrophages of that strain of mouse and no other strains of mice. The receptor is called SIRPα. (It doesn’t really matter.) But, you now have a mouse receptor compatible with human CD47 that prompted us together with additional information to really take this in vivo.

Host-Margot Kern

In the Science paper, you inject these NOD/SCID mice with nanoparticles that have human CD47 attached to them. But you don’t attach the full CD47 protein. Why?

Interviewee-Dennis Discher

Human CD47 is somewhat different within the population.  The receptor, the SIRPα, is certainly different within the human population as it is within different strains of mice.  So we studied a crystal structure of the two bonded together and realized that maybe we could minimize CD47 to a universal donor peptide.  So we simulated it in a computer, showed that it would doc in silico, and then synthesized it, put it on particles, injected it in this NOD/SCID mouse, and showed ultimately that it was inhibiting uptake of our particles by macrophages.

Host-Margot Kern

Discher went on to report in the Science article that he was able to use his CD47-bound nanoparticles to deliver the anti-tumor drug paclitaxel to mice who had been given human-like tumors and that his particles were as good or better at shrinking the mice’s tumors as paclitaxel’s standard carrier, Cremophore, without causing any of the side effects.

For NIBIB News, I’m Margot Kern

Music

 

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Our Mission

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to transform through engineering the understanding of disease and its prevention, detection, diagnosis, and treatment.

Connect with us

  • NIBIB youtube page
  • NIBIB twitter page
  • NIBIB facebook page
  • NIBIB listserv page
  • NIBIB RSS page
  • NIBIB linkedin page
NIH...TURNING DISCOVERY INTO HEALTH®
  • HOME
  • DISCLAIMER
  • POLICIES
  • ACCESSIBILITY
  • FOIA
  • VULNERABILITY DISCLOSURE
  • SITE MAP
  • CONTACT US
  • Department of Health & Human Services
  • USA.gov
  • National Institutes of Health